# InMed (INM) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/INM
## Company Profile
- Ticker: INM
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Canada and listed in the U
## Stock Data
- Close: 1.33 USD
- Market cap: 5037375.76 USD
- Last updated: 2026-10-06
## Business Overview
### Small-Molecule Drug Portfolio Company
InMed Pharmaceuticals has developed cannabinoid-related and other small-molecule candidates for neurological, ophthalmic, and dermatologic diseases. The company is seeking strategic transactions for its legacy development programs.
### INM-901 for Alzheimer's Disease
INM-901 is a small-molecule candidate being explored for Alzheimer's disease. Preclinical work has evaluated potential effects on neuroinflammation, neuronal function, and disease-related pathology.
### INM-089 for Dry AMD
INM-089 is being developed for dry age-related macular degeneration. The program is intended to address retinal degeneration through a differentiated small-molecule mechanism.
### INM-755 Dermatology Program
INM-755 is a topical candidate that has been studied in dermatologic conditions, including symptoms associated with epidermolysis bullosa. It remains part of the portfolio available for licensing or other strategic development.
### Transition from BayMedica
InMed discontinued operations at BayMedica, its rare-cannabinoid manufacturing subsidiary. The remaining strategy emphasizes monetization, licensing, or transfer of the pharmaceutical assets rather than maintaining a vertically integrated commercial cannabinoid business.
## Why The Stock Is Moving

As of Oct 6, 2026, INM was little changed and closed at $1.33. No new same-company headline was identified in the current news window.

## Recent News
- 2023-02-17 22:00 EST — [InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update](https://biopharmsignal.com/news/INM/inmed-reports-second-quarter-fiscal-2023-financial-results-and-provides-business-9740a0f7) — Source: InMed
- 2023-02-10 02:41 EST — [InMed Submits Form 12b-25](https://biopharmsignal.com/news/INM/inmed-submits-form-12b-25-d43a3c91) — Source: InMed
- 2023-01-10 12:30 EST — [InMed Provides Business Update and Milestones for 2023](https://biopharmsignal.com/news/INM/inmed-provides-business-update-and-milestones-for-2023-6371d762) — Source: InMed
- 2022-12-15 23:17 EST — [InMed Announces Results of 2022 Annual General Meeting](https://biopharmsignal.com/news/INM/inmed-announces-results-of-2022-annual-general-meeting-3f330965) — Source: InMed
- 2022-12-12 23:47 EST — [InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor](https://biopharmsignal.com/news/INM/inmed-announces-appointment-of-interim-chief-financial-officer-and-change-of-aud-1c2a1f20) — Source: InMed